Ultrasmall superparamagnetic iron oxide nanoparticles acutely promote thrombosis and cardiac oxidative stress and DNA damage in mice by unknown
RESEARCH Open Access
Ultrasmall superparamagnetic iron oxide
nanoparticles acutely promote thrombosis
and cardiac oxidative stress and DNA
damage in mice
Abderrahim Nemmar1*, Sumaya Beegam1, Priya Yuvaraju1, Javed Yasin2, Saeed Tariq3, Samir Attoub4
and Badreldin H. Ali5
Abstract
Background: Ultrasmall superparamagnetic iron oxide nanoparticles (USPIO) are being developed for several
biomedical applications including drug delivery and imaging. However, little is known about their possible
adverse effects on thrombosis and cardiac oxidative and DNA damage.
Methods: Presently, we investigated the acute (1 h) effect of intravenously (i.v.) administered USPIO in mice
(0.4, 2 and 10 μg/kg). Diesel exhaust particles (DEP; 400 μg/kg) were used as positive control.
Results: USPIO induced a prothrombotic effect in pial arterioles and venules in vivo and increased the plasma
plasminogen activator inhibitor-1 (PAI-1). Both thrombogenicity and PAI-1 concentration were increased by
DEP. The direct addition of USPIO (0.008, 0.04 and 0.2 μg/ml) to untreated mouse blood dose-dependently
induced in vitro platelet aggregation. USPIO caused a shortening of activated partial thromboplastin time
(aPTT) and prothrombin time (PT). Similarly, DEP administration (1 μg/ml) triggered platelet aggregation in vitro
in whole blood. DEP also reduced PT and aPTT. The plasma levels of creatine phosphokinase-MB isoenzyme
(CK-MB), lactate dehydrogenase (LDH) and troponin-I were increased by USPIO. DEP induced a significant
increase of CK-MB, LDH and troponin I levels in plasma. The cardiac levels of markers of oxidative stress
including lipid peroxidation, reactive oxygen species and superoxide dismutase activity were increased by
USPIO. Moreover, USPIO caused DNA damage in the heart. Likewise, DEP increased the markers of oxidative
stress and induced DNA damage in the heart.
Conclusion: We conclude that acute i.v. administration of USPIO caused thrombosis and cardiac oxidative
stress and DNA damage. These findings provide novel insight into the pathophysiological effects of USPIO
on cardiovascular homeostasis, and highlight the need for a thorough evaluation of their toxicity.
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Background
Nanotechnology is a broad interdisciplinary area that in-
volves biochemistry, physics, biology, materials science,
electrical engineering and more [1, 2]. Nanotechnology
holds great promise in numerous fields, including medi-
cine. In the latter field, it has developed rapidly to create
a new application of nanotechnology in medicine known
as nanomedicine which aims at the improvement of tar-
geted drug delivery, better diagnostic and imaging tech-
niques [1, 2]. Nanomedicine develops potential therapies
designed to diagnose and treat specific diseases [1, 2].
However, concerns have been expressed about the pos-
sible adverse effects of nanomaterials [1–3].
Ultrasmall superparamagnetic iron oxide nanoparticles
(USPIO, < 50 nm) have an iron oxide core that is monomer
or polymer-coated/stabilized. They possess highly reactive
surface, uniform particle size distribution, good suspension
and the possibility of additional coating modification by
conjugating with a drug [4–6]. USPIO are being developed
for drug delivery and neuroimaging and imaging of tu-
mours and metastases in the liver, spleen and bone marrow,
and perfusion imaging of atherosclerotic plaque and throm-
bosis [4–7] However, the existing information regarding the
toxicity of USPIO is rather limited, and little attention has
been paid to their potential in vivo toxicity [8]. Moreover,
most information on their in vivo toxicity has been derived
from studies that were not specifically designed to evaluate
their toxicity [7].
It is well-established that particulate air pollution and
some engineered nanoparticles (such as silica) cause
prothrombotic effects [9–11]. Since USPIO are being ad-
ministered directly into the circulation following intra-
venous injection in perfusion imaging of thrombosis [6],
we hypothesized that these nanoparticles can plausibly
interact with the vasculature and circulating cells such
as platelets and could, possibly, aggravate thrombosis.
Moreover, such administered nanoparticles can also reach
the heart and cause oxidative stress and DNA damage.
Therefore, the aim of this study was to investigate the
acute (1 h) effect of intravenously (i.v.) administered
USPIO in mice (0.4, 2 and 10 μg/kg) on thrombosis in
vivo and in vitro and cardiac oxidative stress and DNA
damage. Appropriate positive control particles were used
in the present study, i.e. diesel exhaust particles (DEP)
which are known to cause thrombosis, cardiotoxicity and
oxidative stress [12–14]. The dose of DEP tested (400 μg/
kg or 0.4 mg/kg) is comparable to that used recently by
Tabor et al. for i.v. injection (0.5 mg/kg) in rats [12].
Methods
USPIO and DEP
As described by the manufacturer (Sigma, St. Louis,
MO, USA), the USPIO (magnetite, Fe3O4) used in the
present study have a particle size ranged between 4 and
6 nm (diameter 5 nm, by transmission electron micros-
copy), density 5 mg/mL in H2O [includes total weight of
nanoparticles plus <1.0 % modified short chain poly-
ethylene glycol (PEG) stabilizing ligands], 1 mg/ml Fe
and magnetization >25 emu/g, at 4500Oe.
To confirm their size, we performed transmission elec-
tron microscopy analysis of the USPIO. Thus, droplets
(10 μL) of a suspension of 0.1 mg of USPIO in 500 μL
were placed on matured formvar/carbon film for 30 s.
The samples were then drained and inverted onto drop-
lets of ultrapure water for 1 h before being drained,
dried, and examined in a Philips CM10 Transmission
Electron Microscope.
The DEP were obtained from the National Institute of
Standards and Technology (NIST, Gaithersburg, MD,
USA), and were suspended in sterile saline (NaCl 0.9 %).
These particles were previously analysed by transmission
electron microscopy, and shown to have a substantial
amount of ultrafine (nano) sized particle aggregates, and
larger particle aggregates [15].
The endotoxin concentration in the USPIO solution,
DEP and saline used was quantified, as described by the
manufacturer, by chromogenic Limulus Amebocyte Lysate
(Pierce, Rockford, IL) test. The concentrations were lower
than the detection limit (0.1 EU/ml) in the saline, and
USPIO and DEP solutions.
Animals and i.v. administration of USPIO or DEP
This project was reviewed and approved by our Institu-
tional Review Board and experiments were performed in
accordance with protocols approved by the Institutional
Animal Care and Research Advisory Committee.
USPIO or DEP were suspended in normal saline (NaCl
0.9 %). To minimize aggregation, particle suspensions
were always sonicated (Clifton Ultrasonic Bath, Clifton,
New Jersey, USA) for 15 min and vortexed before their
dilution and prior to i.v. administration.
BALB/C mice (Taconic Farms Inc., Germantown, NY,
USA) weighing 20–25 g were housed in light (12-h
light:12-h dark cycle) and temperature-controlled (22 ±
1 °C) rooms. They had access to commercial laboratory
chow and tap water ad libitum.
The mice were anesthetized with urethane (1 mg/g body
weight, i.p.), and 2 F catheter (Portex, Hythe, UK) was
inserted in the right jugular vein. Either USPIO suspensions
(0.4, 2 and 10 μg/kg) or DEP (400 μg/kg) or saline-only
were i.v. injected (100 μl), and 1 h later various cardiovascu-
lar parameters were assessed.
Experimental thrombosis model in pial arterioles and
venules
The assessment of thrombosis has been performed accord-
ing to a previously described technique [16–19]. Briefly, the
trachea was intubated after induction of anaesthesia with
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urethane (1 mg/g body weight, i.p.), and a 2 F venous cath-
eter (Portex, Hythe, UK) was inserted in the right jugular
vein for the administration of fluorescein (Sigma, St. Louis,
MO, USA). After that, a craniotomy was first performed on
the left side, using a microdrill, and the dura was stripped
open. Only untraumatised preparations were used, and
those showing trauma to either microvessels or underlying
brain tissue were discarded. The animals were then placed
on the stage of a fluorescence microscope (Olympus,
Melville, NY, USA) attached to a camera and DVD re-
corder. A heating mat was placed under the mice and
body temperature was raised to 37 °C, as monitored by
a rectal thermoprobe connected to a temperature reader
(Physitemp Instruments, NJ, USA). The cranial preparation
was moistened continuously with artificial cerebrospinal
fluid of the following composition (mM): NaCl 124, KCl 5,
NaH2PO4 3, CaCl2 2.5, MgSO4.4, NaHCO3 23 and glucose
10, pH 7.3–7.4. A field containing arterioles and venules
15–20 μm in diameter was chosen. Such a field was taped
prior to and during the photochemical insult, which was
carried out by injecting fluorescein (0.1 ml/mouse of 5 %
solution) via the jugular vein, which was allowed to circu-
late for 30–40 s. The cranial preparation was then exposed
to stabilized mercury light. The combination produces
endothelium injury of the arterioles and venules. This, in
turn, causes platelets to adhere at the site of endothelial
damage and then aggregate. Platelets aggregate and the
thrombus forms and grows in size until complete vascular
occlusion. The time, in seconds, was measured from the
photochemical injury until full vascular occlusion (time to
flow stop) in venules. One hour before the administration
of fluorescein, 100 μl of saline (control) or saline containing
either USPIO or DEP was administered via the jugular vein.
The animals were euthanized at the end of the recording
by an overdose of anaesthesia.
Blood collection and analysis
In separate experiments, new mice were anesthetized
and were given i.v. saline (control) or saline containing
either USPIO or DEP as described above. One h later,
the animals’ blood was drawn from the inferior vena
cava in EDTA (4 %) and centrifuged at 4 °C for 15 min
at 3000 rpm, and the plasma samples obtained were
stored at−80 °C until further analysis.
Determination of systemic markers of fibrinolysis and
myocardial membrane damage
The concentration of plasminogen activator inhibitor-1
(PAI-1) (Molecular Innovation, Southfield, MI, USA) was
determined using ELISA Kit. Creatine phosphokinase-MB
isoenzyme (CK-MB), troponin-I and lactate dehydrogen-
ase (LDH) were measured spectrophotometrically using
kits (Roche, Basel, Switzerland).
Measurement of cardiac markers of oxidative stress
The hearts obtained from the animals used above were
quickly rinsed with ice-cold PBS (pH 7.4) before
homogenization in 0.1 M phosphate buffer pH 7.4
containing 0.15 M KCl, 0.1 mM EDTA, 1 mM DTT
and 0.1 mM phenylmethylsulfonylfluoride at 4 °C. The
homogenates were centrifuged for 20 min at 14,000 rpm
to remove cellular debris and supernatants were used for
further analysis. Protein content was measured by Brad-
ford’s method as described before [20–22].
Measurement of reactive oxygen species (ROS): ROS
were measured in the whole cardiac tissue homogenates
which were obtained as described above using 2’, 7’-
Dichlorofluorescein diacetate (DCFDA; Molecular Probes,
Eugene, OR, USA) as a fluorescent probe as described
before [20–22]. The results were normalized as ROS
produced per mg of protein.
NADPH-dependent membrane LPO in the heart hom-
ogenate was determined using TBARS kit purchased
from Cayman Chemical Company (Ann Arbor, MI, USA).
Measurement of superoxide dismutase (SOD) was per-
formed by an ELISA technique with commercially available
kit (Cayman Chemicals, Michigan, USA).
In vitro platelet aggregation in mouse whole blood
The platelet aggregation assay in whole blood was per-
formed, with slight modification, as described before
[23]. After anaesthesia, blood from untreated mice was
withdrawn from the inferior vena cava and placed in cit-
rate (3.2 %), and 100-μl aliquots were added to the well
of a Merlin coagulometer (MC 1 VET; Merlin, Lemgo,
Germany). The blood samples were incubated at 37.2 °C
with either saline (control) or USPIO (0.008, 0.04 and
0.2 μg/ml) or DEP (1 μg/ml) for 3 min, and then stirred
for another 3 min. At the end of this period, 25-μl sam-
ples were removed and fixed on ice in 225 ml cellFix
(Becton Dickinson). After fixation, single platelets were
counted in a VET ABX Micros with a mouse card (ABX,
Montpellier, France). The degree of platelet aggregation
following USPIO or DEP exposure was expressed as a ℅
of control (saline-treated blood).
In vitro measurement of prothrombin time (PT) and
activated partial thromboplastin time (aPTT) in plasma
One hour following either saline or USPIO or DEP ad-
ministration, blood was withdrawn from each mouse, as
described above. The PT was measured [24–26] on
freshly collected, platelet-poor plasma with human, reli-
pidated, recombinant thromboplastin (Recombiplastin;
Instrumentation Laboratory, Orangeburg, NY, USA) in
combination with a Merlin coagulometer MC 1 VET
(Merlin, Lemgo, Germany). The aPTT was measured
[24–26] with automated aPTT reagent (BioMerieux,
Durham, NC, USA) using a Merlin coagulometer MC 1
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VET (Merlin, Lemgo, Germany). Normal plasma used as
reference for both the PT and aPTT was prepared by
pooling equal portions of platelet-poor plasmas from the
blood of six untreated mice.
DNA damage assessment in the heart by COMET assay
Immediately after sacrifice, the heart was removed from
each animal. Single-cell suspensions of the different
hearts were obtained according to the method described
by de Souza et al.[27]. Each collected organ was washed
in a chilled medium (RPMI 1640, 15 % DMSO, 1.8 %
(w/v) NaCl). The heart tissues were placed in 1.5 ml
medium and chopped finely into pieces in a Petri dish
using scissors. The pieces were allowed to settle and the
supernatant was collected in a 15 ml tube. The obtained
cell suspension was centrifuged at 1000 rpm for 5 min
at 40 C. The supernatant was discarded and the pellets
were resuspended in 0.5 ml of the medium. The cell
suspensions were mixed with low melting point agarose
solution (0.65 %) and spread onto agarose (1.5 %)–pre-
coated microscope slides. For each treatment five slides
were prepared, which were incubated in ice cold lysis
buffer (2.5 M NaCl, 10 mM Tris, 100 mM EDTA, 1 %
Triton X-100 and 10 % DMSO) at 40 C for at least 1 h
to remove the cell membranes. After the incubation,
slides were placed in a horizontal electrophoresis unit
and incubated in electrophoresis buffer (0.2 M EDTA,
5 M NaCl, pH 10) for 20 min for DNA unwinding and
the expression of alkali labile sites. Then, electrophor-
esis was conducted for 20 min at 25 V and 300 mA.
After that, the slides were neutralized with Tris buffer
(0.4 M Trizma base, pH 7.5) for 5 min and washed with
methanol. Then the slides were stained with propidium
iodide, as previously described [28, 29]. All these steps
were performed in darkness to prevent additional DNA
damage. The slides were mounted on a fluorescent
microscope and cell scoring was performed. Fifty cells
from each treatment were scored and analyzed for
DNA migration and the average of the five slides from
each group was calculated. The measurement of length
of the DNA migration (i.e. diameter of the nucleus plus
migrated DNA) was calculated using image analysis
Axiovision 3.1 software (Carl Zeiss, Canada) [29, 30].
Statistics
All statistical analyses were performed with GraphPad
Prism Software version 5 (San Diego, CA, USA). To de-
termine whether parameters were normally distributed,
the Kolmogorov–Smirnov statistic normality test was
applied. Comparisons between groups were performed
by one way analysis of variance (ANOVA), followed by
Newman-Keuls multiple-range tests. Data which were
not normally distributed were analyzed with Kruskal-
Wallis test followed by Dunn’s multiple comparison test.
P-values <0.05 are considered as significant.
Results
Transmission electron microscopy analysis of USPIO
Transmission electron microscopy of the USPIO revealed
a homogeneous particle size of 5 nm (range between 4
and 6 nm) (Fig. 1). This confirms the size provided by the
manufacturer.
Effect of USPIO or DEP on photochemically-induced
thrombosis in pial arterioles and venules
Figure 2a illustrates that the i.v. administration of USPIO
caused a significant shortening of the thrombotic oc-
clusion time in the pial arterioles at the dose of 2 μg/kg
(P < 0.05) and 10 μg/kg (P < 0.001). Likewise, Fig. 2b
shows that the i.v. injection of USPIO induced a significant
shortening of the thrombotic occlusion time in pial venules
at the dose of 2 μg/kg (P < 0.01) and 10 μg/kg (P < 0.001).
At the dose studied (400 μg/kg), DEP induced more
shortening in the thrombotic occlusion time in pial ar-
terioles (P < 0.001) and venules (P < 0.001).
Fig. 1 Transmission electron micrographs of the ultrasmall superparamagnetic iron oxide nanoparticles suspension showing the presence of
nanosized particles
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Effect of USPIO or DEP on PAI-1 concentration in plasma
The plasma concentration of PAI-1, an endogenous fac-
tor of fibrinolysis, was significantly increased following
USPIO administration of 2 μg/kg (P < 0.05) and 10 μg/kg
(P < 0.05) compared with the control group (Fig. 3).
DEP induced a significant increase in PAI-1 concentra-
tion (P < 0.001).
In vitro effect of USPIO or DEP on platelet aggregation in
whole blood
Figure 4 illustrates the effect of various concentrations
of USPIO (0.008, 0.04 and 0.2 μg/ml blood) on platelet
aggregation in whole blood in vitro. A concentration-
dependent and significant platelet aggregation was ob-
served after the addition of USPIO to whole blood at
concentrations of 0.04 μg/ml (P < 0.001) and 0.2 μg/ml
(P < 0.001). Likewise, DEP administration (1 μg/ml) in
vitro caused a significant platelet proaggregatory effect
in whole blood (P < 0.001).
Effect of USPIO or DEP on PT and aPTT
The PT and aPTT measured in plasma obtained from mice
i.v. administered with USPIO or DEP are shown in Fig. 5.
In comparison with the value obtained for the control
group, the i.v. administration of USPIO caused a signifi-
cant shortening of PT. The level of significance was
achieved at 0.4 μg/kg (P < 0.01), 2 μg/ml (P < 0.001) and
10 μg/ml (P < 0.01) (Fig. 5a). Similarly, the administra-
tion of USPIO induced a significant shortening of aPTT
at 0.4 μg/ml (P < 0.01), 2 μg/ml (P < 0.01) and 10 μg/ml
(P < 0.01) (Fig. 5b). DEP significantly reduced the PT
(P < 0.001) and aPTT (P < 0.001).
Effect of USPIO or DEP on plasma activities of LDH,
CK-MB and troponin-I
The i.v. administration of USPIO caused a significant
and dose-dependent increase in the levels of LDH, CK-
MB and troponin-I in plasma (Fig. 6a–c). For the LDH,
the increase was statistically insignificant at 0.4 μg/ml,
but it was significant at 2 μg/ml (P < 0.05) and 10 μg/ml
(P < 0.05) (Fig. 6a). Regarding CK-MB, the level of signifi-
cance was achieved at all the studied doses, i.e. 0.4 μg/ml
(P < 0.05), 2 μg/ml (P < 0.01) and 10 μg/ml (P < 0.001)
(Fig. 6b). The troponin-I levels were increased at 10 μg/ml
(P < 0.05) (Fig. 6c). Similarly, DEP significantly augmented
the levels of LDH (P < 0.05), CK-MB (P < 0.05) and tropo-
nin I (P < 0.001).
Effect of USPIO or DEP on cardiac oxidative stress
Figure 7a illustrates that the i.v. administration of USPIO
induced a significant increase of lipid peroxidation in
heart tissue at 0.4 μg/ml (P < 0.001), 2 μg/ml (P < 0.001)
and 10 μg/ml (P < 0.001) compared with control group.
ROS levels in heart tissue were increased at all the stud-
ied doses of USPIO (P < 0.01) (Fig. 7b). Along with the
increase of LPO and ROS, the levels of the antioxidant
SOD were significantly increased (P < 0.001) at all the
Fig. 2 Thrombotic occlusion time in pial arterioles (a) or venules (b)
1 h after the intravenous administration of ultrasmall superparamagnetic
iron oxide nanoparticles (USPIO), diesel exhaust particles (DEP) or saline
(control) in mice. *P< 0.05, **P< 0.01 and ***P< 0.001 compared with
the corresponding saline-treated group. Data are mean ± SEM (n= 6–8)
Fig. 3 Plasminogen activator inhibitor-1 (PAI-1) concentrations in
plasma, 1 h after the intravenous administration of ultrasmall
superparamagnetic iron oxide nanoparticles (USPIO), diesel exhaust
particles (DEP) or saline (control) in mice. *P < 0.05 and ***P < 0.001
compared with the corresponding saline-treated group. Data are
mean ± SEM (n = 6)
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studied doses (Fig. 7c). DEP induced a significant in-
crease of all the assessed markers of oxidative stress, i.e.
LPO (P < 0.001), ROS (P < 0.001) and SOD (P < 0.001).
Effect of USPIO on cardiac DNA damage
Figure 8 shows that compared with control group, the
i.v. injection of USPIO induced DNA damage in the
heart at 0.4 μg/ml (P < 0.001), 2 μg/ml (P < 0.001) and
Fig. 4 Direct in vitro effect after the administration of ultrasmall
superparamagnetic iron oxide nanoparticles (USPIO), diesel exhaust
particles (DEP) or saline (control) on platelet aggregation in whole
blood of untreated mice. Platelet aggregation in untreated whole
blood 3 min after the addition of either saline or USPIO was
assessed. The degree of platelet aggregation following USPIO
exposure was expressed as a percent of control (saline-treated
blood). Data are mean ± SEM (n = 4). *P < 0.001 compared with
saline-treated blood within the same group
Fig. 5 Prothrombin time (PT, a) and activated partial thromboplastin
time (aPTT, b) measured 1 h after the intravenous administration of
ultrasmall superparamagnetic iron oxide nanoparticles (USPIO), diesel
exhaust particles (DEP) or saline (control) in mice. *P < 0.01 and
**P < 0.001 compared with the corresponding saline-treated group.
Data are mean ± SEM (n = 4–6)
Fig. 6 Lactate dehydrogenase (LDH, a) and creatine phosphokinase-MB
(b) and troponin-I (c) in plasma 1 h after the intravenous administration
of ultrasmall superparamagnetic iron oxide nanoparticles (USPIO), diesel
exhaust particles (DEP) or saline (control) in mice. *P< 0.05, **P< 0.01
and ***P< 0.001 compared with the corresponding saline-treated group.
Data are mean ± SEM (n= 4–6)
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10 μg/ml (P < 0.0.01). Likewise, DEP caused significant
DNA damage in the heart (P < 0.001).
Discussion
We showed here that acute (1 h) i.v. administration of
USPIO caused prothrombotic events in pial arterioles
and venules in vivo, platelet aggregation in whole blood
in vitro and shortening of PT and aPTT. The concentra-
tion of PAI-1 was increased by USPIO. Markers of myo-
cardial membrane damage in plasma including CK-MB,
LDH and troponin-I were significantly increased by
USPIO. Moreover, USPIO induced oxidative stress in
the heart evidenced by increase of LPO, ROS and SOD,
and caused cardiac DNA damage. All the aforementioned
endpoints were increased by the administration of the
positive control particles, namely DEP.
Commercially available USPIO are surface coated with
materials such as silicon, dextran, citrate and PEGylated
starch and are mainly used as contrast agents in target
organs [8]. In the present study, we tested 5 nm USPIO
with PEG stabilizing ligands. PEG has been broadly uti-
lised in the formulation of nanoparticles for biomedical
applications, both because of its biocompatibility and its
effectiveness in masking nanoparticles from opsonins
[31]. These nanoparticles were administered i.v. to the
mice. This route of exposure imitates their potential use
in clinical settings [4]. Moreover, their small size allow
them to cross the capillary beds and gain access to vari-
ous organs such as lung, brain kidney, spleen, liver and
heart [32]. Previously, when dextran-coated superpara-
magnetic iron oxide nanoparticles were examined as a
contrast agent in subjects, their adverse effects (head-
ache, back pain, vasodilatation, and urticarial) were re-
ported to be mild or moderate in severity and of short
duration [33]. A dose of 2.6 mg of iron per kg was ap-
plied [33]. In experimental arthritis model in mice, doses
of 3.3 mg Fe/kg or 33.3 mg Fe/kg were injected i.v. [34].
The doses of USPIO (0.4, 2 and 10 μg per kg) used in
our study in mice have low iron content of 0.0004, 0.002
and 0.01 μg Fe per kg, respectively. However, the amount
of iron injected is not the sole parameter that determines
the toxicity of nanoparticles in general [3, 35]. In fact, it is
well established that nanoparticles have unique features
including their very small size, large surface area and cel-
lular penetration capacity which are responsible for their
specific biological responses that differ from larger particle
of similar chemical composition [3, 35, 36]. Recently, it
has been shown that i.v. injected polyacrylic acid coated γ-
Fe2O3 nanoparticles (10 mg/kg) in healthy BALB/cJ mice
induced a decrease in the mean arterial blood pressure
(MAP) associated with a decreased contractility of small
mesenteric arteries [37]. In anaesthetized pigs, it has been
demonstrated that dimercaptosuccinic acid coated super-
paramagnetic iron oxide nanoparticles (MF66-labelled
12 nm, core nominal diameter and OD15 15 nm); at 0.5,
or 2.0 mg/kg injected i.v. induced a transient yet signifi-
cant decrease in MAP [38]. Particles remained in the
circulation for up to 30 min and were accumulated in
the liver, spleen and lungs [38]. With regard to human
exposure situation, pharmacokinetic data related to the
liposome-encapsulated doxorubicin nanoparticles, used
in cancer therapy, reported plasma concentrations of more
than 10 μg/ml [39]. The last concentration is much higher
than that used in the present in vivo study. In fact, the
highest dose of nanoparticles used here which is 10 μg/kg
Fig. 7 Lipid peroxidation (LPO, a), reactive oxygen species (ROS, b)
and superoxide dismutase (D) levels in heart tissues 1 h after the
intravenous administration of ultrasmall superparamagnetic iron
oxide nanoparticles (USPIO), diesel exhaust particles (DEP) or saline
(control) in mice. *P < 0.01 and **P < 0.001 compared with the
corresponding saline-treated group. Data are mean ± SEM (n = 6–8)
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(0.25 μg/mouse of 25 g) would correspond to approxi-
mately 0.16 μg/ml, assuming a circulating mouse blood
volume of 1.5 ml. One of the reasons why we wanted to
use lower dose of USPIO in our study is because we
wanted to test the possible exacerbating effect of USPIO
on an in vivo photochemical injury model of thrombosis
in the pial cerebral arterioles and venules. In clinical set-
tings, patients who will be potentially injected with these
nanoparticles, for diagnosis or treatment purposes, will
likely have pre-existing diseases (e.g. cardiovascular dis-
eases). Therefore, we can speculate that those patients
may conceivably exhibit increased susceptibility to adverse
cardiovascular effect of USPIO as compared with healthy
peoples. In this sense, the minor photochemical trauma
to endothelium used in our experiments may have
pathophysiological relevance [40]. Superficial erosion,
or microscopic areas of desquamation of endothelial
cells, occurs frequently in both humans and in animals
with experimentally-induced atherosclerosis [40]. The
doses of DEP used in vivo (400 μg/kg or 0.4 mg/kg)
and in vitro (1 μg/ml) are similar to those used recently
to study the prothrombotic effects of DEP in vivo and in
vitro [12, 13]. Our data show that the i.v. administration of
USPIO for 1 h caused a significant and dose-dependent
shortening of the thrombotic occlusion time, showing that
USPIO have prothrombotic effect. Several previous studies
have reported the use of USPIO for perfusion imaging of
atherosclerotic plaque and thrombosis [7]. For example, in
a recent study, USPIO were injected i.v. at different time
points after photothrombotic infarction in mice, and it
was possible to follow vessel occlusion in vivo by USPIO-
enhanced high-field MRI [41]. It has been reported that
i.v. administration of polystyrene nanoparticles in ham-
sters, rats and mice, and DEP in rats and mice cause in
vivo thrombogenicity [15, 36, 42–44]. Nevertheless, the
possible prothrombotic effect of USPIO has, as far as we
are aware, never been reported so far.
In the present study, we also found a significant in-
crease of circulating PAI-1 following the administration
of USPIO. PAI-1 is the most potent endogenous inhibi-
tor of fibrinolysis and is involved in the pathogenesis of
several cardiovascular diseases [45, 46]. An increase of
PAI-1 has been observed following exposure to either
DEP [47] or silica nanoparticles [11].
Our model of thrombosis depends on platelet activation
and aggregation [17]. Consequently, we wanted to verify
Fig. 8 DNA migration in the heart tissues, 1 h after the intravenous administration of ultrasmall superparamagnetic iron oxide nanoparticles
(USPIO), diesel exhaust particles (DEP) or saline (control) in mice. Images illustrating the quantification of the DNA migration by the Comet assay
under alkaline conditions, in control (b), USPIO (c–e) or DEP (f). *P < 0.001 compared with the corresponding saline-treated group. Data are
mean ± SEM (n = 5)
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whether and to what extent can USPIO directly activate
platelet and cause their aggregation in whole blood in
vitro. Since the highest dose of nanoparticles tested, pres-
ently, in vivo (10 μg/kg or 0.25 μg/mouse) would corres-
pond to approximately 0.16 μg/ml blood, we selected to
test in vitro concentrations which are relevant to our in
vivo study, i.e. 0.2 μg/ml being the highest concentration
and 2 lower ones (0.04 and 0.008 μg/ml). Our data show
that low concentrations of USPIO cause a significant and
dose-dependent proaggregatory effect, confirming the in
vivo prothrombotic findings. Although USPIO are devel-
oped for i.v. administration, and hence, the study of their
interaction with circulating cells such as platelets is crit-
ical, little is known about their potential effect on platelet
aggregation. Several studies focused on designing func-
tionalized USPIO to target activated platelets for the study
atheroma pathogenesis [7, 48]. However, other types of
particles such silica, polystyrene, DEP or TiO2 have previ-
ously been reported to induce platelet aggregation in vitro
[11, 23, 36, 44, 49, 50]. Furthermore, we demonstrated the
activation of PT and aPTT in plasma of mice in vivo ad-
ministered with various doses of USPIO. This effect re-
flects hypercoagulability caused by USPIO and confirm
the in vivo and in vitro prothrombotic effects of these
nanoparticles. High concentration of maghemite nano-
particles bioferofluids (0.38 mg/ml Fe2O3) has been re-
ported to shorten PT but, on the other hand, it caused
prolongation of aPTT [51]. Here, we also found that
DEP caused a shortening of PT and aPTT, confirming
our earlier findings [13]. Our data showed significant
increments in cardiac enzyme levels of LDH, CK-MB
and troponin-I (at 10 μg/kg), which may be attributed
to the myocardial membrane damage produced by
USPIO and the leakage of these enzymes into blood
[52]. To gain more insight into the cardiac toxicity of
USPIO, we assessed the effect of these nanoparticles on
oxidative stress and DNA damage in the heart tissue.
Oxidative stress is a key pathological process in a var-
iety of pathophysiological conditions affecting various
organs such as the lung, heart, kidney or liver and is
characterized by the formation of a wide range of ROS,
which can cause severe DNA, protein, and lipid damage
leading to cellular dysfunction and death [53]. Iron
oxide nanoparticles found either in the environment or
in biomedical settings are readily taken up by the cells
and cause the generation of free radicals leading to oxi-
dative stress [8, 54]. It has been shown that even stabi-
lized iron oxide particles with coatings such as dextran
or citric acid may cause oxidative stress [55]. More re-
cently, to mitigate oxidative stress-induced by iron oxide
nanoparticles, antioxidant polymer poly(trolox) was for-
mulated into nanoparticles coated with an antibody di-
rected towards platelet endothelial cell adhesion
molecule-1 [56]. These active targeting nanoparticles
have shown to adhere to human umbilical vein endo-
thelial cells, internalize, and reduce oxidative stress in-
duced by iron oxide particles [56]. Nevertheless, the
effect of USPIO on oxidative stress and DNA damage
in the heart has never been reported so far. Our data
show a significant increase in LPO and ROS in the
heart. Moreover, we found a significant increase of the
antioxidant SOD in the heart. This indicates that the
development of oxidative stress is accompanied by an
adaptive response that counterbalances the potentially
damaging activity of oxygen free radicals by antioxidant
defense mechanisms. Increase of SOD following expos-
ure to silica nanoparticles has been recently reported in
mouse erythrocytes [57] and in the heart of mice ex-
posed to cigarette smoke [21]. Likewise, in the present
study, DEP induced a significant increase of all the
markers of oxidative stress studied. For evaluating gen-
etic damage, the gel electrophoresis of a single cell
(Comet assay) was used to assess DNA damage in the
heart following USPIO administration. Our data show a
significant DNA damage in the heart after the acute ad-
ministration of USPIO. DEP caused similar effect. We
speculate that ROS generation and oxidative stress
caused by USPIO induced DNA damage in the heart.
Such an effect has not been reported before. An in vitro
study showed that iron oxide nanoparticles caused DNA
damage and apoptosis through ROS generation in human
breast cancer cell line [58]. A recent study in rats using
high doses of Fe2O3-30 nm nanoparticles (500–2000 mg/
kg) given orally did not assess DNA damage in heart but
showed no genotoxicity in circulating leukocytes between
6 h and 72 h post-exposure [59].
Conclusion
We conclude that acute i.v. administration of USPIO
exerts procoagulatory effect in vivo and in vitro and
cause cardiac oxidative stress and DNA damage. These
findings provide novel insight into the pathophysio-
logical effects of USPIO on cardiovascular system, and
highlight the need for a comprehensive assessment of
their toxicity before their clinical use. Additional studies
are needed to investigate the effect of various coating such
as dextran on the toxicity of USPIO and the mechanisms
underlying the effects of USPIO on platelet activation in
human blood.
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